8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Alison Yan Zhang, Ian D. Davis, Hayley Thomas, Ronan Andrew McLaughlin, Thean Hsiang Tan, David Pook, Gavin Marx, Robert Zielinski, Shahneen Sandhu, Alastair Thomson, M. Neil Reaume, Scott North, John McCaffrey, Ray McDermott, Nicola Jane Lawrence, Lisa G. Horvath, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney (2025). 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5090.
